MedPath

Assessment of the Effect of Atorvastatin on Prevention of CIN in Patients Undergoing Coronary Angiography

Phase 3
Conditions
Contrast Induced Nephropathy
Interventions
Registration Number
NCT02113540
Lead Sponsor
Isfahan University of Medical Sciences
Brief Summary

As the effect of statin use before the angiography to prevent contrast induced nephropathy (CIN) is not well-known, the aim of the current study is to assess the effect of atorvastatin on prevention of CIN in patients undergoing coronary angiography.

Detailed Description

Not available

Recruitment & Eligibility

Status
UNKNOWN
Sex
All
Target Recruitment
Not specified
Inclusion Criteria
  • having chronic stable angina who were referred for coronary angiography
  • non-pregnant female subjects
  • no history of diabetes mellitus
  • no history of renal failure
  • no history of single kidney
  • no history of cardiogenic shock
  • no history of unstable angina
  • no history of myocardial infarction
  • no history of hypersensitivity to statins
  • no history of previous intravascular contrast injection during one month before admission
Exclusion Criteria
  • glomerular filtration rate (GFR) <60
  • cardiogenic shock

Study & Design

Study Type
INTERVENTIONAL
Study Design
PARALLEL
Arm && Interventions
GroupInterventionDescription
preoperation statin groupAtorvastatintaking atorvastatin 12 hours before the procedure
Primary Outcome Measures
NameTimeMethod
Contrast induced nephropathy (CIN) incidence48 hours after the procedure

CIN is determined as an increase in post-procedural serum creatinine of \> 0.5 mg/dl or \> 25% from baseline in the absence of any other causes

Secondary Outcome Measures
NameTimeMethod
serum creatinine (Cr) level48 hours after the procedure
© Copyright 2025. All Rights Reserved by MedPath